State criteria designate certain GLP1s as preferred and others as subject to additional priorauthorization or steptherapy requirements
Glucagon receptor activation: Increases hepatic glucose output (relevant in fasted states), stimulates lipolysis in adipose tissue, and raises basal metabolic rate through thermogenic mechanisms
Cea Soriano L, Johansson S, Stefansson B, Rodriguez LA
The Evaluate Renal Function with Semaglutide Once Weekly (FLOW) trial, published earlier this year, is the first to specifically investigate kidney outcomes with GLP-1 receptor agonists
This adverse event should be reported to the MHRA via the Yellow Card scheme (yellowcard.mhra.gov.uk) to contribute to ongoing pharmacovigilance
Our physicians stay current on the science and translate it into safe, effective treatment plans for each patient